Title
Enteropathogen Changes After Rotavirus Vaccine Scale-up
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Oyola-Lozada M.G.
Colquechagua Aliaga F.D.
Vittet Mondonedo M.D.
Taquiri C.
Tilley C.D.H.
Simons C.M.P.
Meza R.A.
Bern C.
Saito M.
Naval Medical Research Unit No. 6
Johns Hopkins University
Publisher(s)
American Academy of Pediatrics
Abstract
OBJECTIVES: To inform next steps in pediatric diarrhea burden reduction by understanding the shifting enteropathogen landscape after rotavirus vaccine implementation. METHODS: We conducted a case-control study of 1788 medically attended children younger than 5 years, with and without gastroenteritis, after universal rotavirus vaccine implementation in Peru. We tested case and control stools for 5 viruses, 19 bacteria, and parasites; calculated coinfection-adjusted attributable fractions (AFs) to determine pathogen-specific burdens; and evaluated pathogen-specific gastroenteritis severity using Clark and Vesikari scales. RESULTS: Six pathogens were independently positively associated with gastroenteritis: norovirus genogroup II (GII) (AF 29.1, 95% confidence interval [CI]: 28.0-32.3), rotavirus (AF 8.9, 95% CI: 6.8-9.7), sapovirus (AF 6.3, 95% CI: 4.3-7.4), astrovirus (AF 2.8, 95% CI: 0.0-4.0); enterotoxigenic Escherichia coli heat stable and/or heat labile and heat stable (AF 2.4, 95% CI: 0.6-3.1), and Shigella spp. (AF 2.0, 95% CI: 0.4-2.2). Among typeable rotavirus cases, we most frequently identified partially heterotypic strain G12P[8] (54 of 81, 67%). Mean severity was significantly higher for norovirus GII-positive cases relative to norovirus GII-negative cases (Vesikari [12.7 vs 11.8; P < .001] and Clark [11.7 vs 11.4; P = .016]), and cases in the 6- to 12-month age range relative to cases in other age groups (Vesikari [12.7 vs 12.0; P = .0002] and Clark [12.0 vs 11.4; P = .0016]). CONCLUSIONS: Norovirus is well recognized as the leading cause of pediatric gastroenteritis in settings with universal rotavirus vaccination. However, sapovirus is often overlooked. Both norovirus and sapovirus contribute significantly to the severe pediatric disease burden in this setting. Decision-makers should consider multivalent vaccine acquisition strategies to target multiple caliciviruses in similar countries after successful rotavirus vaccine implementation.
Volume
149
Issue
1
Language
English
OCDE Knowledge area
Farmacología, Farmacia
Pediatría
Scopus EID
2-s2.0-85123226699
PubMed ID
Source
Pediatrics
ISSN of the container
00314005
Sponsor(s)
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose. FUNDING: Supported by the National Institutes of Health Fogarty International Center (1R25 TW009340-01), Thrasher Research Fund Early Career Award, Pat Tillman Foundation Tillman Military Scholar Award, American Society of Tropical Medicine and Hygiene Centennial Travel Award, Clements-Mann Vaccine Fund, Henry K. and Lola Beye Endowed Award, and R. Bradley Sack Family Award to Dr Ballard. Drs Mayta and Sanchez, Ms Cabrera, and Drs Bern, Saito, and Gilman were supported by the National Institutes of Health (1R21AI099737-01). The funders did not have a role in the design or conduct of the study. Funded by the National Institutes of Health (NIH). POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Sources of information:
Directorio de Producción Científica
Scopus